Satyarx Pharma Innovations Profile
Key Indicators
- Authorised Capital ₹ 11.00 Cr
as on 06-11-2024
- Paid Up Capital ₹ 9.94 Cr
as on 06-11-2024
- Company Age 4 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 76.54%
(FY 2023)
- Profit 18.85%
(FY 2023)
- Ebitda 19.52%
(FY 2023)
- Net Worth -431.31%
(FY 2023)
- Total Assets 48.69%
(FY 2023)
About Satyarx Pharma Innovations
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 11.00 Cr and a paid-up capital of Rs 9.94 Cr, as per Ministry of Corporate Affairs (MCA) records.
Ande Reddy, Satyanarayana Chavali, and Saroja Chavali serve as directors at the Company.
- CIN/LLPIN
U73100TG2020PTC142629
- Company No.
142629
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Aug 2020
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Rangareddy, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Satyarx Pharma Innovations?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ande Reddy  | Director | 16-Nov-2020 | Current |
| Satyanarayana Chavali | Director | 08-Aug-2020 | Current |
| Saroja Chavali | Director | 08-Aug-2020 | Current |
Financial Performance and Corporate Structure Insights of Satyarx Pharma Innovations.
Satyarx Pharma Innovations Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 76.54% increase. The company also saw a substantial improvement in profitability, with a 18.85% increase in profit. The company's net worth observed a substantial decline by a decrease of 431.31%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Satyarx Pharma Innovations?
In 2023, Satyarx Pharma Innovations had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Satyatx Pharma Services LlpActive 3 years 2 days
Satyanarayana Chavali and Saroja Chavali are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Satyarx Pharma Innovations?
Satyarx Pharma Innovations has a workforce of 47 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Satyarx Pharma Innovations, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Satyarx Pharma Innovations's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
